Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review

3 Feb 2025

Abstract excerpt

In recent years, pembrolizumab has demonstrated significant efficacy in treating tumors characterized by a high tumor mutational burden and high microsatellite instability. Tropomyosin receptor kinase (TRK) inhibitors have shown considerable efficacy against tumors harboring neurotrophic receptor tyrosine kinase (NTRK) fusion genes, highlighting the growing importance of personalized medicine in cancer treatment....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Neurofibromatosis and Schwannoma Cases
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39895082
DOI: 10.1093/jjco/hyaf015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated reviewPMID 39895082Read ↗

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical AspectsSemantic proximity Read ↗

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma NetworkSemantic proximity Read ↗

NTRK1-3 Fusions in Sarcomas: Prevalence, Significance, and Clinical Implications – A Systematic ReviewSemantic proximity Read ↗

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric PatientsSemantic proximity Read ↗

Identification of Dual STRN-NTRK2 Rearrangements in a High Grade Sarcoma, With Good Clinical Response to First-line Larotrectinib TherapySemantic proximity Read ↗

The First Case Treated with Larotrectinib of a Novel TMTC2-NTRK3 Fusion Undifferentiated High-Grade Pleomorphic Sarcoma of the ChestSemantic proximity Read ↗

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapySemantic proximity Read ↗

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasSemantic proximity Read ↗

Prevalence of neurotrophic tropomyosin receptor kinase ( NTRK ) fusion gene positivity in patients with solid tumors in JapanSemantic proximity Read ↗

Surgical Resection and Targeted Therapy in a Pediatric NTRK-Rearranged Low- Grade Spindle Cell Sarcoma: A Case ReportSemantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

Testing algorithm for identification of patients with TRK fusion cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.